How will the findings presented at the ESMO Congress affect David J. Pinato?
Pinato presented Phase 3 data on adjuvant cancer treatment at ESMO David J. Pinato presented a poster detailing the results of a Phase I study regarding adjuvant treatment for pancreatic cancer. The presentation was part of the larger body of work shared at the ESMO Congress in Madrid, Spain. The specific study focused on intismeran autogene combined with FOLFIRINOX.
- Effect
- Mixed
- How direct
- Stated in the reporting
- When
- Right away
- The story
- Gone quiet
How it reaches David J. Pinato
-
Researchers presented Phase 3 clinical data at the European Society for Medical Oncology Congress on September 21, 2026. The presentations included a Presidential Symposium led by Georgina V. Long regarding the Phase 3 study of intismeran autogene combined with pembrolizumab for adjuvant treatment of resected stage IIB-IV melanoma. Additionally, David J. Pinato presented findings from a Phase I study on adjuvant intismeran autogene combined with FOLFIRINOX for pancreatic ductal adenocarcinoma.
The full event1independent outlet -
The presentation was a poster session held during the ESMO Congress in Madrid, Spain. The specific study evaluated intismeran autogene combined with FOLFIRINOX for adjuvant treatment of resectable pancreatic ductal adenocarcinoma. This presentation took place on Sunday, October 25, from 12:00 to 12:45 PM CET.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- pr-inside.com Sep 21
-
medical oncologist
Everything about David J. Pinato
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Abstract 3151P was presented by David J. Pinato.pr-inside.com
- The presentation was about adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma.pr-inside.com
- The poster session took place on Sunday, October 25, from 12:00 to 12:45 PM CET.pr-inside.com
Why it matters
For medical oncologists like Pinato, presenting new data at major congresses like ESMO is crucial for sharing scientific findings. This presentation outlines the results of a study into a novel treatment approach for pancreatic cancer.
What we don't know yet
- What were the specific outcomes of the Phase I study regarding intismeran autogene combined with FOLFIRINOX?
- How does this data compare to current standard treatments for adjuvant pancreatic cancer?
What would change this answer
Reporting
- pr-inside.comSep 21
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. It explains possible effects; it is not investment advice.